Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer

Kawano, Toshirou; Nakamura, Yoshiyasu; Yanoma, Shunsuke; Kubota, Akira; Furukawa, Madoka; Miyagi, Youhei; Tsukuda, Mamoru

doi:10.1016/j.anl.2003.09.005

Cited by 48 publications

(41 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25). Kawano et al found CD44s and CD44v6 staining correlated with prognosis in a series of 57 patients treated with surgery and radiotherapy (35). Zhao et al analyzed margins after surgery for 112 HNSCC patients and found that CD44v6 presence in these margins, detected with immunohistochemistry, was predictive of recurrence (36).…”

Section: Discussionmentioning

confidence: 99%

CD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer

Jong

Pramana

Wal

et al. 2010

Clinical Cancer Research

158

102

View full text Add to dashboard Cite

Purpose: To find molecular markers from expression profiling data to predict recurrence of laryngeal cancer after radiotherapy.Experimental Design: We generated gene expression data on pre-treatment biopsies from 52 larynx cancer patients. Patients developing a local recurrence were matched for T-stage, subsite, treatment, gender and age with non-recurrence patients. Candidate genes were then tested by immunohistochemistry on tumor material from a second series of 76 patients. Both series comprised early stage cancer treated with radiotherapy alone. Finally, gene expression data of eight larynx cancer cell lines with known radiosensitivity were analyzed.Results: Nineteen patients with a local recurrence were matched with 33 controls. Gene sets for hypoxia, proliferation and intrinsic radiosensitivity did not correlate with recurrence, whereas expression of the putative stem cell marker CD44 did. In a supervised analysis, probes for all three splice variants of CD44 on the array appeared in the top 10 most significantly correlated with local recurrence. Immunohistochemical analysis of CD44 expression on the independent validation series confirmed CD44's predictive potential. In 8 larynx cancer cell lines, CD44 gene expression did not correlate with intrinsic radiosensitivity although it did correlate significantly with plating efficiency, consistent with a relationship with stem cell content.Conclusions: CD44 was the only biological factor tested which significantly correlated with response to radiotherapy in early stage larynx cancer patients, both at the mRNA and protein levels. Further studies are needed to confirm this and to assess how general these findings are for other head and neck tumor stages and sites. Clin Cancer Res; 16(21); 5329-38. ©2010 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

CD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer

Jong

Pramana

Wal

et al. 2010

Clinical Cancer Research

158

102

View full text Add to dashboard Cite

show abstract

“…The features of the 19 eligible studies are listed in Table 1; 1 study was from each of the following countries: Spain (Esteban et al 2005),Turkey (Yuce et al 2011), Italy (Staibano et al 2007), Finland (Kokko et al 2011), and the USA (Janisiewicz et al 2012), two studies were from Japan (Kawano et al 2004;Uwa et al 2011), and 12 were from China (Song et al 1999;Wang et al 2000;Zhao et al 2003;Xu et al 2003;Wang et al 2004;Qiu et al 2006;Huang et al 2007;Lu et al 2008;Ma et al 2009;Gao 2009;Guo et al 2009;Lu et al 2011). Three studies focused on pharyngeal cancer, 14 focused on laryngeal cancer, and 2 studied both laryngeal and pharyngeal cancer.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…None of the patients received neo-adjuvant radiotherapy or chemotherapy prior to surgery. The patients in the study of Kawano et al (2004) received surgery and radiotherapy after diagnosis, and the patients of other studies were treated with curative surgery.…”

Section: Follow-up Timementioning

confidence: 99%

“…Among the exons, ten exons are constitutively expressed to produce a 85-to 90-Kd isoform named as CD44 standard form (CD44s), whereas other isoforms called CD44 variants (CD44v), are generated by alternatively spliced transcripts (Zoller 2011). Up to date, CD44v6 was the most reported isoform in pharyngolaryngeal cancer (Song et al 1999;Wang et al 2000;Kawano et al 2004;Andratschke et al 2005;Staibano et al 2007;Huang et al 2007;Lu et al 2008;Guo et al 2009;Gao 2009). …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CD44 Expression Is Predictive of Poor Prognosis in Pharyngolaryngeal Cancer: Systematic Review and Meta-Analysis

Chai

Liu

Wang

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Pharyngolaryngeal cancer is one of the most common head and neck cancer worldwide, and the early diagnosis and prognosis prediction are still difficult because of lacking in reliable cell markers. Although the expression of CD44 has been reported to correlate with poor prognosis of pharyngolaryngeal cancer in most literatures, some controversies still exist. Since the limited patient numbers within independent studies, here we performed a meta-analysis to clarify the correlations between CD44 expression and clinicopathological features and prognosis in pharyngolaryngeal cancer. A search of PubMed, ISI Web of Science and China National Knowledge Infrastructure databases (up to June 2013) was performed. Nineteen studies with 1,405 patients met the inclusion criteria. The expression of pan-CD44, including all variant isoforms, was detected in 58.0% (14.1-79.2%) specimens, while CD44-v6 (variant isoform 6 of CD44) was expressed in 54.8% (12-79.2%). In pooled analysis, CD44 expression was significantly associated with larger tumor size (T category, RR (relative risk) = 1.21, 95% CI: 1.01-1.46), lymph nodes metastasis (N category, RR = 1.94, 95% CI: 1.38-2.73) and poor prognosis [3-year overall survival (OS): RR = 0.70, 95% CI: 0.53-0.91; 5-year OS: RR = 0.66, 95% CI: 0.66-0.94]. In the stratified analysis of CD44 isoforms, high expression of CD44-v6 was related with a poor 5-year OS rate (RR = 0.53, 95% CI: 0.37-077). We propose that CD44 expression is associated with tumor size, lymph node metastasis, and poor prognosis in pharyngolaryngeal cancer patients.

show abstract

“…There are reports that support the loss, gain, or absence of change in expression of certain CD44 family members during the process of metastasis in HNSCC cells. 12,22,23 However, the general theme that emerges indicates a predominant loss of expression of certain CD44 isoforms during the progression to metastasis. Reduced expression of CD44s, v4, v5, v6, v7, and v9 have all been correlated with lymph node metastasis.…”

Section: Cell-substrate Adhesion Molecules: Integrins and Cd44mentioning

confidence: 99%